Loading...
XNYSZBH
Market cap21bUSD
Dec 27, Last price  
106.87USD
1D
-0.35%
1Q
-1.25%
Jan 2017
3.56%
Name

Zimmer Biomet Holdings Inc

Chart & Performance

D1W1MN
XNYS:ZBH chart
P/E
20.78
P/S
2.88
EPS
5.14
Div Yield, %
0.94%
Shrs. gr., 5y
0.60%
Rev. gr., 5y
-1.40%
Revenues
7.39b
+6.55%
2,980,900,0003,286,100,0003,495,400,0003,897,500,0004,121,100,0004,095,400,0004,220,200,0004,451,800,0004,471,700,0004,623,400,0004,673,300,0005,997,800,0007,683,900,0007,824,100,0007,932,900,0007,982,200,0007,024,500,0006,827,300,0006,939,900,0007,394,200,000
Net income
1.02b
+342.52%
541,800,000732,500,000834,500,000773,200,000848,600,000717,400,000596,900,000760,800,000755,000,000761,000,000720,100,00049,700,000302,900,0001,839,600,000-379,200,0001,131,600,000-137,400,000401,600,000231,400,0001,024,000,000
CFO
1.58b
+23.11%
862,200,000878,200,0001,040,700,0001,084,400,0001,038,100,0001,117,500,0001,193,500,0001,176,900,0001,151,900,000963,100,0001,052,800,000862,800,0001,632,200,0001,582,300,0001,747,400,0001,585,800,0001,204,500,0001,499,200,0001,284,700,0001,581,600,000
Dividend
Sep 30, 20240.24 USD/sh
Earnings
Feb 06, 2025

Profile

Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. The company is headquartered in Warsaw Indiana, Indiana and currently employs 19,000 full-time employees. The firm's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The firm manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The firm's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
URL
https://www.zimmerbiomet.com/en
IPO date
Jul 25, 2001
Employees
18,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,394,200
6.55%
6,939,900
1.65%
6,827,300
-2.81%
Cost of revenue
2,542,500
2,425,500
2,396,200
Unusual Expense (Income)
NOPBT
4,851,700
4,514,400
4,431,100
NOPBT Margin
65.61%
65.05%
64.90%
Operating Taxes
42,200
112,300
53,500
Tax Rate
0.87%
2.49%
1.21%
NOPAT
4,809,500
4,402,100
4,377,600
Net income
1,024,000
342.52%
231,400
-42.38%
401,600
-392.29%
Dividends
(200,900)
(201,200)
(200,100)
Dividend yield
0.79%
0.75%
0.75%
Proceeds from repurchase of equity
(692,200)
(48,300)
BB yield
2.71%
0.18%
Debt
Debt current
952,900
544,300
1,605,100
Long-term debt
5,216,700
5,319,500
5,649,100
Deferred revenue
740,900
Other long-term liabilities
751,400
1,053,800
548,500
Net debt
5,722,200
5,471,500
7,541,700
Cash flow
Cash from operating activities
1,581,600
1,284,700
1,499,200
CAPEX
(602,800)
(187,900)
(152,000)
Cash from investing activities
(778,900)
(529,200)
(503,600)
Cash from financing activities
(763,500)
(843,800)
(1,306,000)
FCF
4,305,100
4,280,400
4,661,100
Balance
Cash
415,800
375,700
378,100
Long term investments
31,600
16,600
(665,600)
Excess cash
77,690
45,305
Stockholders' equity
10,204,400
9,389,800
10,069,400
Invested Capital
19,157,110
18,694,495
20,973,100
ROIC
25.41%
22.19%
20.61%
ROCE
24.76%
23.50%
20.58%
EV
Common stock shares outstanding
209,700
210,300
210,400
Price
121.70
-4.55%
127.50
0.36%
127.04
-17.55%
Market cap
25,520,490
-4.82%
26,813,250
0.31%
26,729,216
-16.20%
EV
31,250,390
32,291,450
34,276,616
EBITDA
5,803,400
5,440,800
5,368,800
EV/EBITDA
5.38
5.94
6.38
Interest
201,200
164,800
208,400
Interest/NOPBT
4.15%
3.65%
4.70%